Rhys Whomsley

1.3k total citations
36 papers, 928 citations indexed

About

Rhys Whomsley is a scholar working on Pharmacology, Molecular Biology and Genetics. According to data from OpenAlex, Rhys Whomsley has authored 36 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 8 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in Rhys Whomsley's work include Pharmacogenetics and Drug Metabolism (10 papers), Estrogen and related hormone effects (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Rhys Whomsley is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Estrogen and related hormone effects (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Rhys Whomsley collaborates with scholars based in Belgium, United Kingdom and Netherlands. Rhys Whomsley's co-authors include M. Strolin Benedetti, E. Baltes, Jean‐Marie Nicolas, Jean‐Baptiste Watelet, Eugène Baltes, Keith F. Tipton, François‐Xavier Mathy, Italo Poggesi, Philippe Collart and Colin N. Young and has published in prestigious journals such as Radiology, Environment International and Drug Discovery Today.

In The Last Decade

Rhys Whomsley

33 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rhys Whomsley Belgium 17 244 211 210 153 145 36 928
Kazutomi Kusano Japan 20 127 0.5× 310 1.5× 269 1.3× 241 1.6× 72 0.5× 46 902
Katalin Monostory Hungary 25 202 0.8× 459 2.2× 646 3.1× 318 2.1× 170 1.2× 93 1.8k
Nina Hanke Germany 20 158 0.6× 299 1.4× 308 1.5× 193 1.3× 126 0.9× 40 1.1k
Nobuo Inotsume Japan 17 159 0.7× 212 1.0× 243 1.2× 221 1.4× 39 0.3× 90 1.1k
Noriko Ohashi Japan 14 115 0.5× 243 1.2× 313 1.5× 182 1.2× 26 0.2× 27 1.1k
Nasir Zahid Canada 18 75 0.3× 253 1.2× 288 1.4× 121 0.8× 74 0.5× 24 877
Päivi Taavitsainen Finland 18 117 0.5× 226 1.1× 722 3.4× 318 2.1× 53 0.4× 26 1.1k
B. Sinués Spain 16 123 0.5× 309 1.5× 464 2.2× 238 1.6× 29 0.2× 35 874
Thierry Cresteil France 8 341 1.4× 280 1.3× 466 2.2× 221 1.4× 24 0.2× 13 1.1k
Ernesto Callegari United States 15 158 0.6× 421 2.0× 396 1.9× 342 2.2× 62 0.4× 29 1.3k

Countries citing papers authored by Rhys Whomsley

Since Specialization
Citations

This map shows the geographic impact of Rhys Whomsley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhys Whomsley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhys Whomsley more than expected).

Fields of papers citing papers by Rhys Whomsley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rhys Whomsley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhys Whomsley. The network helps show where Rhys Whomsley may publish in the future.

Co-authorship network of co-authors of Rhys Whomsley

This figure shows the co-authorship network connecting the top 25 collaborators of Rhys Whomsley. A scholar is included among the top collaborators of Rhys Whomsley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rhys Whomsley. Rhys Whomsley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kruhlak, Naomi L., Marianne Schmidt, Roland Froetschl, et al.. (2024). Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regulatory Toxicology and Pharmacology. 150. 105640–105640. 39 indexed citations
3.
Backhaus, Thomas, et al.. (2023). Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment. Environment International. 183. 108379–108379. 8 indexed citations
4.
Durán, Rafael, Julien Namur, Florentina Pascale, et al.. (2019). Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer. Radiology. 293(3). 695–703. 15 indexed citations
5.
Denys, Alban, et al.. (2017). Vandetanib-eluting Radiopaque Beads: In vivo Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization. Theranostics. 7(8). 2164–2176. 10 indexed citations
6.
Benedetti, M. Strolin, Rhys Whomsley, Italo Poggesi, et al.. (2009). Drug metabolism and pharmacokinetics. Drug Metabolism Reviews. 41(3). 344–390. 112 indexed citations
7.
Watelet, Jean‐Baptiste, et al.. (2009). Defence mechanisms of olfactory neuro-epithelium: mucosa regeneration, metabolising enzymes and transporters.. PubMed. 5 Suppl 13. 21–37. 8 indexed citations
8.
Benedetti, M. Strolin, Keith F. Tipton, Rhys Whomsley, & E. Baltes. (2007). Factors affecting the relative importance of amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans. Journal of Neural Transmission. 114(6). 787–791. 6 indexed citations
9.
Benedetti, M. Strolin, Keith F. Tipton, & Rhys Whomsley. (2007). Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?. Fundamental and Clinical Pharmacology. 21(5). 467–480. 36 indexed citations
10.
Benedetti, Manuel, et al.. (2007). Drug metabolism in the paediatric population and in the elderly. Drug Discovery Today. 12(15-16). 599–610. 47 indexed citations
11.
Benedetti, M. Strolin, et al.. (2007). Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1‐antihistamine cetirizine. Fundamental and Clinical Pharmacology. 22(1). 19–23. 19 indexed citations
12.
13.
Benedetti, M. Strolin, Rhys Whomsley, & Eugène Baltes. (2006). Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opinion on Drug Metabolism & Toxicology. 2(6). 895–921. 64 indexed citations
14.
Benedetti, M. Strolin, René Coupez, Rhys Whomsley, et al.. (2004). Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica. 34(3). 281–300. 50 indexed citations
15.
Benedetti, M. Strolin, Rhys Whomsley, Jean‐Marie Nicolas, Colin N. Young, & E. Baltes. (2003). Pharmacokinetics and metabolism of 14 C-levetiracetam, a new antiepileptic agent, in healthy volunteers. European Journal of Clinical Pharmacology. 59(8-9). 621–630. 80 indexed citations
16.
Nicolas, Jean‐Marie, Rhys Whomsley, Philippe Collart, & J. Roba. (1999). In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chemico-Biological Interactions. 123(1). 63–79. 30 indexed citations
17.
Smith, H J, et al.. (1996). Some Flavones and Isoflavones as Inhibitors of Human Placental 17β‐Hydroxysteroid Dehydrogenase In‐vitro. Pharmacy and Pharmacology Communications. 2(1). 21–23. 1 indexed citations
18.
Whomsley, Rhys, et al.. (1993). Substituted 1-[(benzofuran-2-YL)-phenylmethyl]-imidazoles as potent inhibitors of aromatase in vitro and in female rats in vivo. The Journal of Steroid Biochemistry and Molecular Biology. 44(4-6). 675–676. 41 indexed citations
19.
Whomsley, Rhys, et al.. (1993). Some 1-, and 3-Substituted 3-(4 - Aminophenyl)Pyrrolidine-2,5-Diones as Selective Inhibitors of Aromatase. Journal of enzyme inhibition. 6(4). 317–330. 7 indexed citations
20.
Slevin, M L, et al.. (1989). The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemotherapy and Pharmacology. 24(5). 329–331. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazutomi Kusano Breakdown of academic impact, for papers by Katalin Monostory Breakdown of academic impact, for papers by Nina Hanke Breakdown of academic impact, for papers by Nobuo Inotsume Breakdown of academic impact, for papers by Noriko Ohashi Breakdown of academic impact, for papers by Nasir Zahid Breakdown of academic impact, for papers by Päivi Taavitsainen Breakdown of academic impact, for papers by B. Sinués Breakdown of academic impact, for papers by Thierry Cresteil Breakdown of academic impact, for papers by Ernesto Callegari
Rankless by CCL
2026